



Exhibit 99.1

First Quarter 2008 Webcast

April 24, 2008

Safe Harbor Statement

Statements contained in this presentation that are forward-looking are based on current expectations that are subject to a number of uncertainties and risks, and actual results may differ materially. This presentation is being made on April 24, 2008, and Alcon does not undertake any obligation to update any of the forward-looking statements or forward-looking information. Although Alcon believes that these statements are based on reasonable assumptions within the bounds of its knowledge of its businesses and operations, there are a number of factors that may cause actual results to differ from these statements. Factors that might cause these differences include, but are not limited to, the uncertainty of market acceptance of our products by the worldwide medical community; uncertainty of clinical trial results for expanded FDA approval submissions for our current products and initial approval of our products under development; product liability claims; the occurrence of excessive property and casualty, general liability or business interruption losses, for which we are self insured; manufacturing issues; and risks inherent in international transactions. For additional factors, which could cause actual results to differ from expectations, reference is made to the periodic reports filed by the company with the Securities and Exchange Commission under the Securities Exchange Act of 1934 as amended. Additional information about risk factors also can be found in the Company's Form 20-F filed with the SEC dated March 18, 2008, under the heading "Risk Factors". All these documents are available publicly and upon request from the Alcon Investor Relations Department at 817-551-8805 or www.alcon.com.

Business Overview

Cary Rayment

Chairman, President & CEO

Sales Highlights


1 st Qtr		Q1 08	Q1 07	Growth
<i>(dollars in millions)</i>				
Global Sales		\$ 1,536.4	\$ 1,322.7	16.2%
			Constant Currency*	9.4%
Net Earnings	Reported	\$ 429.4	\$ 346.2	24.0%
Diluted EPS	Reported	\$ 1.43	\$ 1.14	25.4%

- Q1 2007 included a \$20.8 million after-tax impact of charges related to refractive impairment

* Constant currency sales growth is a non-GAAP measure presented to give investors a better comparison of operations between years.

Q1 2008 Geographic Sales and Growth


Q1 2008 Sales by Geography




* Constant currency sales growth is a non-GAAP measure presented to give investors a better comparison of operations between years.

Pharmaceutical Sales

Q1 2008 Sales by Therapy



1st Qtr




* Constant currency sales growth is a non-GAAP measure presented to give investors a better comparison of operations between years.

(dollars in millions)

TRAVATAN® Franchise Growth


**PGA Market Share since TRAVATAN Z® Launch
(September 2006 vs. February 2008)**



Source: WK Health


Glaucoma growth in Japan

TRAVATANZ™ Share of Japanese Prostaglandin Market



Source: IMS


Continued DuoTrav™ Market Development



Source: IMS

Patanol® Family Continues as Market Leader


U.S. Patanol® Family Market Share Growth



Source: WK Health

Patanol® Share Growth in Japan


Japan Patanol® Unit Market Share Growth



Source: IMS

Patanase® Approval and U.S. Nasal Market


- Approved by FDA on April 15
- Fast onset of action vs. steroids
- Leverage Patanol® brand equity




Source: Wolters Kluwer Health

Surgical Sales

Q1 2008 Sales by Therapy



1st Qtr




* Constant currency sales growth is a non-GAAP measure presented to give investors a better comparison of operations between years.

(dollars in millions)


AcrySof® IOLs Driving Growth

Global Dollar Sales by Quarter of AcrySof® IOLs




* Sourced by Market Scope

Advanced Technology IOL Sales Trend




Phaco Procedures Performed by Machine



Source: Q1 2008 Company Research



Positive Trend in Refractive Surgical Sales

Refractive Sales Growth



Consumer Eye Care Sales

Q1 2008 Sales by Therapy




* Constant currency sales growth is a non-GAAP measure presented to give investors a better comparison of operations between years.

(dollars in millions)

Evolution of Alcon's CLC Products

OPTI-FREE® Branded Market Share by Product



Source: Nielsen Research

Financial Review


Rick Croarkin

Senior Vice President, Finance and Chief Financial Officer

Q1 Gross Profit

Reported

+16.9%



2008 includes:

- WaveLight® integration charges
- Government rebate variations
- Global pricing pressures


2007 includes:

- \$24.0 mio costs related to the 2007 refractive impairment

Q1 Operating Income

Reported

+24.1%



2008 includes:


- WaveLight® integration charges
- SG&A:
 - Sales force additions
 - Shared services center

2007 includes:

- \$32.7 mio costs related to the 2007 refractive impairment

Q1 Net Earnings

Reported



2008 includes:


- Decline in non-operating income (Global credit markets)
- Improvement in effective tax rate

2007 includes:

- \$20.8 mio after-tax impact of the 2007 refractive impairment

Q1 Diluted EPS

Reported



2008 includes:


- Share count adjustment
- Share repurchase plan changes

2007 includes:

- Includes (\$0.07) effect from the refractive impairment

Cash Flows Analysis

Cash Flows from Operations



2008 Full Year Financial Guidance Revision

- **Sales range of \$6.4 to \$6.5 billion**
 - Increase due to exchange rate changes
- **Diluted earnings per share range of \$6.39 to \$6.49**
 - Reflects increased sales due to exchange
 - Investment income slightly lower than originally expected
 - Includes retroactive tax savings due to the R&D tax credit in Q4
- **Includes costs to establish Swiss Shared Service and Marketing Centers and to integrate refractive operations**
- **Expect effective tax rate range of 13.5% to 14.5% to decline by 200 to 300 basis points by 2010**



Non-GAAP Constant Currency Reconciliation

(dollars in millions)	GAAP Growth Rate	Exchange Rate Changes	Constant Currency Growth Rate
Global Sales	16.2%	(6.8)	9.4%
Pharmaceutical	13.3%	(5.5)	7.8%
Surgical	20.2	(8.2)	12.0
Consumer	12.1	(5.9)	6.2
United States	5.9%	--	5.9%
Developed International	24.2	(13.8)	10.4
Emerging Markets	28.6	(11.0)	17.6

Note: Percent Change in Constant Currency calculates sales growth without the impact of foreign exchange fluctuations. Management believes constant currency sales growth is an important measure of the company's operations because it provides investors with a clearer picture of the core rate of sales growth due to changes in unit volumes and local currency prices. This measure is considered a non-GAAP financial measure as defined by Regulation G promulgated by the U.S. Securities and Exchange Commission. Certain reclassifications have been made to prior year amounts to conform with current year presentation.